News · 26 weeks52+50%
2026-04-192026-10-11
Mix2490d
- Market14(58%)
- SEC Filings9(38%)
- Other1(4%)
Latest news
25 items- NEWSPhase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricidesSHELTON, CT / ACCESS Newswire / October 13, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, said today that its Phase IIA Ebola Treatment Clinical Trial of NV-387 Oral Gummies is progressing well.The Phase IIA part of the clinical trial is designed to evaluate different dosage regimens of the oral gummies for the treatment of different severity levels of the Ebola Bundibugyo virus infection and disease in the current Ebola Outbreak in the Democratic Republic of Congo ("DRC").The trial is enrolling and is expected to continue enrolling persons exhibiting different disease severity levels, in the "Dry Stage"
- SECSEC Form DEF 14A filed by NanoViricides Inc.DEF 14A - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd Investment Conference in Fort Lauderdale, Florida.ABOUT NANOVIRICIDESNanoViricides, Inc. (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomedicines for antiviral therapy.We are at the forefronts of fighting viral diseases that have global pandemic potential, presenting unmet medical needs, and accounting for over $70 Billion in Market Size.Our first drug, a revolutionary broad-spectrum antiviral nanomedicine called NV-387 has entered Phase II clinical trial for the T
- NEWSNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 LivesSHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus (BDBV) and other Ebola viruses in the Democratic Republic of Congo ("DRC").The trial is proceeding as designed. This clinical trial is being conducted in two parts. Enrollment in the first part, Phase IIA, began on or about September 23, 2026. Patients are being enrolled slowly, in a cautious approach, because NV-387 is a new chemical entity. As the clinical experience with N
- SECNanoViricides Inc. filed SEC Form 8-K: Leadership Update8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical TrialsSHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the Securities and Exchange Commission (SEC) on Monday, September 28, 2026. The report can be accessed at the SEC website (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001379006/000110465926111390/nnvc-20260630x10k.htm).Accomplishments in Reported Fiscal Year ending June 30, 2026In the fiscal year 2026, we have achieved a substantial level of accomplishments. We have focused on regulatory advancement of our broad spectrum antiviral drug NV- 387.We received approval for Phase II clinical
- SECSEC Form 10-K filed by NanoViricides Inc.10-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricidesSHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") has started enrolling and dosing patients at an Ebola Treatment Center in the Ituri province.This clinical trial is registered in the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077.The clinical trial is entitled with a descriptive
- NEWSPhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricidesSHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of first patients in the Democratic Republic of Congo (DRC).This clinical trial was registered in the Pan African Clinical Trials Registry database (pactr.samrc.ac.za). The unique identification number for this clinical trial is PACTR202609506749917.The clinical trial is entitled: "An adaptive international, multi-center, randomized, open-label, interventional, parallel group, phase II (IIa and IIb) clinical trial t
- NEWSClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricidesSHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") is scheduled to start next week at an Ebola Treatment Center in the Ituri province."NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that it is effective against Ebola in the this clinical trial," said Anil R. Diwan, PhD, President of the Company, adding, "The Bundibugyo vir
- PRA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The global antiviral drugs market was valued at roughly $42.3 billion in 2025 and is projected to reach approximately $57.8 billion by 2034. But those numbers only tell part of the story. The bigger opportunity may be
- NEWSClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR CongoSHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") was successfully registered in the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077.The clinical trial is entitled with a descriptive title: "An adaptive, multi-centre Phase IIA/IIB clinical trial of NV-387 oral gummies plus optimised
- SECSEC Form 424B3 filed by NanoViricides Inc.424B3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form EFFECT filed by NanoViricides Inc.EFFECT - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for MeaslesSHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides an update on its Measles Drug Treatment Program.While CDC is reviewing the two recent measles-related fatalities in Pennsylvania, the total number of confirmed measles cases in the USA has reached 2,903 as of August 27, 2026, in comparison to 2,289 confirmed cases in the whole year of 2025, indicating continuing expansion of measles1. Cases of Measles have been rising globally for different reas
- SECSEC Form S-3 filed by NanoViricides Inc.S-3 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSThe Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin SoonSHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo ("DRC").Professor Patrick Katoto has been appointed as the principal investigator to lead this clinical trial. Dr. Katoto 1 is Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health ("CTDGH"), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic Unive
- NEWSNanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola OutbreakSHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses, from the local regulatory agency ACOREP in the Democratic Republic of Congo (DRC).NanoViricides has retained Om Sai Clinical Research Private Limited, India, (Om Sai CRO) as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and
- SECNanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the TrialSHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies, after having filed an application to the local regulatory agency ACOREP, as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC). The Company explains that it has already raised the financing to support this clinical trial."The financing we closed yesterday is sufficient to support the additional expenses from the anticipated Ebola clinical trial of NV-387 Oral Gumm
- SECSEC Form 424B5 filed by NanoViricides Inc.424B5 - NANOVIRICIDES, INC. (0001379006) (Filer)
- SECSEC Form 424B5 filed by NanoViricides Inc.424B5 - NANOVIRICIDES, INC. (0001379006) (Filer)
- NEWSNanoViricides Announces Pricing of ~$3.8 Million Registered Direct OfferingSHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 2,516,339 shares of common stock for gross proceeds of approximately US$3.8 million in a registered direct offering (the "Offering").
- NEWSAs Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for EbolaSHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC).NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and other renowned experts and with support from a well k
- SECNanoViricides Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - NANOVIRICIDES, INC. (0001379006) (Filer)
NNVC FAQ
6 questionsWhat does NanoViricides Inc. do?
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases...Where does NNVC stock trade?
NanoViricides Inc. (NNVC) is listed on AMEX.What sector and industry is NNVC in?
NanoViricides Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NNVC?
NanoViricides Inc. has had 1 recent analyst action on file. The most recent action was from Alliance Global Partners: Buy on 2025-12-16.What companies are similar to NNVC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NNVC side-by-side with any of them on Quantisnow.How can I track NNVC on Quantisnow?
Quantisnow aggregates NanoViricides Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NNVC to receive live email and push alerts on every new disclosure.